choosing the correct parp inhibitor for prostate cancer
Published 5 months ago • 169 plays • Length 1:01Download video MP4
Download video MP3
Similar videos
-
1:31
tackling disease progression whilst using parp inhibitors for prostate cancer
-
0:31
which mutations benefit most from parp inhibitors in prostate cancer?
-
1:35
parp inhibitors for the treatment of metastic castration-resistant prostate cancer
-
3:47
parp inhibitors for metastatic hormone sensitive prostate cancer
-
2:09
current perspectives from clinical trials using parp inhibitors for prostate cancer
-
1:24
luparp: 177lu-psma-617 and parp inhibitor combination for prostate cancer
-
0:57
when is the optimal time to use parp inhibitors in prostate cancer patients?
-
2:30
parp inhibitors plus novel endocrine agents for patients with metastatic prostate cancer
-
1:21
combining a parp and pd-l1 inhibitor to treat prostate cancer
-
3:13
impact of specific mutations on parp inhibition in prostate cancer
-
1:25
parp inhibitors: their applications and efficacy against prostate cancer
-
4:02
the emerging role of parp inhibitors in prostate cancer
-
1:34
combination therapies for the treatment of prostate cancer
-
2:15
asco gu 2023: highlights in prostate cancer
-
2:02
unanswered questions regarding the use of parp inhibitors for patients with mcrpc
-
0:33
circulating tumor cells in management of patients with castration-resistant prostate cancer
-
1:32
dr. chang discusses the use of parp inhibitors in prostate cancer
-
1:53
the evolving role of parp inhibitors in mcrpc
-
3:21
predicting pd-1 checkpoint inhibitor sensitivity in prostate cancer: potential molecular biomarkers